What Are the 3 Cancers With the Highest Cure Rates? (2026 Update)

According to Korea's national cancer registry statistics for 2019–2023, the cancers with the highest 5-year relative survival rates are thyroid cancer (100.2%), prostate cancer (96.9%), and breast cancer (94.7%), in that order. However, these figures are nationwide Korean statistics, not the results of any particular hospital, and individual outcomes can vary significantly depending on tumor histology and stage.

Key Takeaways

• Thyroid cancer has a 5-year relative survival rate of 100.2%, the highest of the three cancers, meaning survival is no different from that of the general population of the same age (National Cancer Registry Statistics, 2019–2023).
• Prostate cancer has a 5-year relative survival rate of 96.9%, up 37.7 percentage points from patients diagnosed in 1993–1995 (National Cancer Registry Statistics, 2019–2023).
• Breast cancer has a 5-year relative survival rate of 94.7%, though treatment and prognosis vary greatly depending on subtype (hormone receptor status and HER2) (National Cancer Registry Statistics, 2019–2023).
• All three figures are population averages, not predictors of individual outcomes, and treatment choices should be made in consultation with your care team.

Why Does Thyroid Cancer Have the Highest Survival Rate?

• Thyroid cancer is the most frequently diagnosed cancer in Korea, and papillary and follicular carcinoma—which account for the vast majority of cases—tend to have a favorable course.
• More than 35,000 cases were diagnosed in Korea in 2023 alone, and widespread use of ultrasound screening means a high proportion are caught at a small size (National Cancer Registry Statistics).
• However, this figure combines all thyroid cancer types together; medullary carcinoma and anaplastic carcinoma behave very differently and should not be viewed through the same lens.
• For tumors 1 cm or smaller that are not in a high-risk location, active surveillance with regular ultrasound monitoring—rather than immediate surgery—is one of the standard options.

Why Has Prostate Cancer Survival Steadily Improved?

• The widespread use of PSA blood testing has increased the proportion of cases diagnosed while still confined to the prostate, which is cited as the driver behind rising survival rates.
• Prostate cancer often progresses slowly, making it one of the rare cancers where active surveillance—monitoring at set intervals without immediate treatment—is a standard option for low-risk patients.
• Treatment decisions are not based on stage alone but on a combined risk assessment incorporating PSA level, Gleason score (grade group), age, and life expectancy; surgery, radiation therapy, and hormone therapy are chosen together with the care team based on the individual situation.
• The 5-year relative survival rate for prostate cancer in the U.S. SEER statistics is 98.2% (SEER 2016–2022), but differences in diagnostic timing and population composition make direct cross-country comparisons difficult.

Why Do Outcomes Differ Even Within the Same Breast Cancer Survival Rate?

• Breast cancer is not a single disease; it is viewed as several distinct diseases with different courses and treatments depending on subtype, classified by hormone receptor status (ER, PR), HER2, and Ki-67.
• Stage 0 (carcinoma in situ) is treated with surgery and radiation therapy; stages 1–2 center on breast-conserving surgery or mastectomy; and stage 3 HER2-positive or triple-negative breast cancer typically receives neoadjuvant chemotherapy before surgery as the standard approach.
• Korea offers a national mammography screening program every two years starting at age 40, with about 30,000 cases diagnosed in 2023 alone (National Cancer Registry Statistics). Because diagnosis tends to occur at a younger age than in Western countries, experience with breast-conserving and reconstructive surgery is well developed.
• Your specific subtype and stage are far more important than the overall survival rate in determining the direction of your treatment.

FAQ — Whose Results Do These Survival Rates Reflect?

These are nationwide Korean statistics, not the results of any specific hospital (National Cancer Registry Statistics 2019–2023, National Cancer Center Korea Central Cancer Registry). Under Korean medical law, individual hospital outcome data cannot be used in advertising, and results for the same cancer can vary greatly depending on tumor histology and stage.

FAQ — Can Treatment Be Delayed for Cancers With High Survival Rates?

It depends on the cancer. For low-risk papillary thyroid cancer and low-risk prostate cancer, monitoring with regular testing is one of the standard options. But for breast cancer, the sequence of treatment itself can matter greatly depending on subtype—for example, neoadjuvant chemotherapy before surgery. Whether to monitor or treat immediately is decided by the care team based on test results and risk classification.

Sources and Disclaimer

• This article was prepared based on National Cancer Registry Statistics 2019–2023 (National Cancer Center Korea Central Cancer Registry), SEER 2016–2022 statistics (U.S. National Cancer Institute), and general information at the level of patient guidelines from the National Cancer Information Center and NCCN.
• This content is intended for general medical information purposes only. Diagnosis, treatment methods, and outcomes may vary depending on the individual's condition. Accurate diagnosis and treatment decisions should always be made in consultation with a qualified medical professional.